Figure 6.
Figure 6. HemA macrophages respond to rFVIIIFc treatment similarly to healthy individuals; plasma samples from individuals with hemophilia exhibit compromised antioxidant function. Macrophages from healthy donors and inhibitor-negative HemA patients were treated with IgG1, rFVIII, or rFVIIIFc for 6 hours, and RNA was isolated. Gene expression changes of HO-1 (n = 16 healthy donors and n = 7 HemA patients) (A) and PPARγ (n = 15 healthy donors and n = 7 HemA patients) (B) were measured by qPCR. (C) Antioxidative capacity of healthy vs inhibitor-negative vs inhibitor-positive HemA plasma samples (n = 27 each) shows significant impairment in hemophilia patients. Mean ± SE; *P ≤ .05, **P ≤ .01, ***P ≤ .005.

HemA macrophages respond to rFVIIIFc treatment similarly to healthy individuals; plasma samples from individuals with hemophilia exhibit compromised antioxidant function. Macrophages from healthy donors and inhibitor-negative HemA patients were treated with IgG1, rFVIII, or rFVIIIFc for 6 hours, and RNA was isolated. Gene expression changes of HO-1 (n = 16 healthy donors and n = 7 HemA patients) (A) and PPARγ (n = 15 healthy donors and n = 7 HemA patients) (B) were measured by qPCR. (C) Antioxidative capacity of healthy vs inhibitor-negative vs inhibitor-positive HemA plasma samples (n = 27 each) shows significant impairment in hemophilia patients. Mean ± SE; *P ≤ .05, **P ≤ .01, ***P ≤ .005.

Close Modal

or Create an Account

Close Modal
Close Modal